— Sunesis Pharmaceuticals (NASDAQ: SNSS) reported loss of $0.05 per share in the fourth quarter of 2019, vs $0.07 per share loss expected.
— Net revenue rose to $2.1 billion, vs. $310,000 expected. The growth in topline was driven by revenue recognized from the upfront payments received under the license agreements with DOT-1 and Denovo.
— Cash and cash equivalents rose to $34.6 million, from $13.7 million a year ago. The growth was primarily due to net proceeds from the issuance of common and preferred stock, and proceeds from the SVB loan.
— SNSS shares fell over 2% immediately following the announcement.
Most Popular
CCL Earnings: Carnival Corp. Q4 2024 revenue rises 10%
Carnival Corporation & plc. (NYSE: CCL) Friday reported strong revenue growth for the fourth quarter of 2024. The cruise line operator reported a profit for Q4, compared to a loss
Key metrics from Nike’s (NKE) Q2 2025 earnings results
NIKE, Inc. (NYSE: NKE) reported total revenues of $12.4 billion for the second quarter of 2025, down 8% on a reported basis and down 9% on a currency-neutral basis. Net
FDX Earnings: FedEx Q2 2025 adjusted profit increases; revenue dips
Cargo giant FedEx Corporation (NYSE: FDX), which completed an organizational restructuring recently, announced financial results for the second quarter of 2025. Second-quarter earnings, excluding one-off items, were $4.05 per share,
